The consumer genetic Testing Service has agreed to a $3.5 billion deal with a blank check firm sponsored by British billionaire Richard Branson.

Well, the company will be getting a stock listing the rial appeals and needed cash and height.

Over 10 million people have used 23 may be included, which tells you things about your ancestry and interesting medical facts like are at risk for certain genetic diseases or how fast you metabolize caffeine.

The problem for the company is simply making money.

Branson might help spice up the services appeal.

Revenue has fallen by about half over the past two years as fewer people take the test.

23 May expects to lose money until at least 2025 but they're roughly $1 billion in cash.

23 meal be left with after the deal.

ISA Time to use genetic data for something else.

Helping develop drugs.

There is one cancer drug in early trials.

In collaboration with GlaxoSmithKline, the deal still looks incredibly toppy.

The equity is estimated to be worth around $4.5 billion.

That's a huge sum.